In preclinical experiments, the SGLT2 inhibitors, Empagliflozin and Canagliflozin have reduced weight gain in mouse models of obesity [20,21]. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.